LUMINOS-101: PVSPRIO plus pembrolizumab in recurrent glioblastoma скачать в хорошем качестве

LUMINOS-101: PVSPRIO plus pembrolizumab in recurrent glioblastoma

Oncolytic viral therapy represents a promising therapeutic strategy under investigation for the treatment of glioblastoma. Andrew Sloan, MD, Case Western Reserve University, Cleveland, OH, shares the details on the Phase II LUMINOS-101 trial, investigating PVSRIPO with pembrolizumab in recurrent glioblastoma. PVSRIPO is a recombinant oncolytic poliovirus, engineered to express the human rhinovirus type 2 internal ribosomal entry site. Data from early phase trials have shown PVSRIPO to be well tolerated and provide significant survival benefits. Additionally, evidence of synergy between PVSRIPO and pembrolizumab has been shown in animal models, providing the rationale for combining both agents in the trial. Trial recruitment has begun, with an aim to enroll 30 patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.